Choosing Statins: a Review to Guide Clinical Practice

Overview

Journal Arch Endocrinol Metab

Specialty Endocrinology

Date 2020 Nov 9

PMID 33166435

Citations 9

Authors

Roberta de Padua Borges

Nathalia Abi Habib Degobi

Marcello Casaccia Bertoluci

Affiliations

Soon will be listed here.

Abstract

Statins are among the most widely prescribed medicines in the world and have proved their value in reducing cardiovascular events and mortality. Many patients report adverse effects that lead to interruption of treatment. This review aims to individualize statin treatment, considering efficacy for reducing cardiovascular risk and safety, in the setting of specific diseases, to minimize the side effects and improve compliance. We gathered evidence that may help clinicians to choose specific statins in different clinical situations, such as the risk of new diabetes, chronic kidney disease, liver disease, human immunodeficiency virus infection, organ transplant, heart failure and elderly people. Efficacy of statins is well established in a large number of clinical conditions. Therefore, main objective is to revise statin in specific clinical settings, based on pharmacokinetics, safety, drug metabolism and interactions to provide the best choice in different clinical scenarios.

Citing Articles

Association between statin use and 30-day mortality among patients with sepsis-associated encephalopathy: a retrospective cohort study.

Chen J, Chen J, Li L Front Neurol. 2025; 15():1371314.

PMID: 39801716 PMC: 11720963. DOI: 10.3389/fneur.2024.1371314.

L-Theanine Ameliorates Obesity-Related Complications Induced by High-Fat Diet in Mice: Insights from Transcriptomics and Metabolomics.

Du Z, Wu G, Cheng H, Han T, Li D, Xie Z Foods. 2024; 13(18).

PMID: 39335905 PMC: 11431230. DOI: 10.3390/foods13182977.

Lipid management strategies for diabetic patients align with an evidence-based guideline.

Kargar M, Zare N, Jafarzadeh Kohneloo A, Afra F, Hadidi E, Gholami K Daru. 2024; 32(2):665-673.

PMID: 39240497 PMC: 11554954. DOI: 10.1007/s40199-024-00534-x.

Atorvastatin lowers breast cancer risk by reversing an early tumorigenic signature.

Foda M, Salem M, Alakwaa F, El-Khawaga O Sci Rep. 2024; 14(1):17803.

PMID: 39090164 PMC: 11294600. DOI: 10.1038/s41598-024-67706-2.

Rosuvastatin treatment alone cannot alleviate lupus in murine model: a pilot study.

Baek W, Lee S, Lee S, Suh C J Rheum Dis. 2023; 30(3):198-203.

PMID: 37476679 PMC: 10351369. DOI: 10.4078/jrd.2023.0021.

References

Buchacz K, Baker R, Palella Jr F, Shaw L, Patel P, Lichtenstein K . Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2012; 18(1):65-75. DOI: 10.3851/IMP2450. View

Hsue P . Mechanisms of Cardiovascular Disease in the Setting of HIV Infection. Can J Cardiol. 2019; 35(3):238-248. DOI: 10.1016/j.cjca.2018.12.024. View

Gu Q, Paulose-Ram R, Burt V, Kit B . Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief. 2014; (177):1-8. View

Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T . Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006; 49(8):1881-92. DOI: 10.1007/s00125-006-0269-5. View

Maeda T, Horiuchi N . Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. J Biochem. 2009; 145(6):771-81. DOI: 10.1093/jb/mvp035. View

Streja E, Gosmanova E, Molnar M, Soohoo M, Moradi H, Potukuchi P . Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. JAMA Netw Open. 2019; 1(6):e182311. PMC: 6324660. DOI: 10.1001/jamanetworkopen.2018.2311. View

Sica D, Gehr T . Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol. 2002; 11(1):48-55. DOI: 10.1111/j.1076-7460.2002.01422.x. View

Pose E, Napoleone L, Amin A, Campion D, Jimenez C, Piano S . Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2019; 5(1):31-41. DOI: 10.1016/S2468-1253(19)30320-6. View

Chamberlain L . Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001; 507(3):357-61. DOI: 10.1016/s0014-5793(01)03007-1. View

10.

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

11.

Packer M . Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications. Eur J Heart Fail. 2018; 20(7):1100-1105. DOI: 10.1002/ejhf.1183. View

12.

Matsushita K, van der Velde M, Astor B, Woodward M, Levey A, de Jong P . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-81. PMC: 3993088. DOI: 10.1016/S0140-6736(10)60674-5. View

13.

Rogers J, Jhund P, Perez A, Bohm M, Cleland J, Gullestad L . Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail. 2014; 2(3):289-97. DOI: 10.1016/j.jchf.2013.12.007. View

14.

Cui J, Zhou R, Han S, Wang T, Wang L, Xie X . Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis. J Clin Pharm Ther. 2018; 43(4):556-570. DOI: 10.1111/jcpt.12690. View

15.

Deedwania P, Stone P, Merz C, Cosin-Aguilar J, Koylan N, Luo D . Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007; 115(6):700-7. DOI: 10.1161/CIRCULATIONAHA.106.654756. View

16.

Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

17.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H . Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013; (12):CD008623. DOI: 10.1002/14651858.CD008623.pub2. View

18.

de Jager D, Grootendorst D, Jager K, van Dijk P, Tomas L, Ansell D . Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009; 302(16):1782-9. DOI: 10.1001/jama.2009.1488. View

19.

Lee M, Sattar N, McMurray J, Packard C . Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. Curr Atheroscler Rep. 2019; 21(10):41. PMC: 6660504. DOI: 10.1007/s11883-019-0800-z. View

20.

Zhang Z, Wu P, Zhang J, Wang S, Zhang G . The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res. 2016; 105:74-83. DOI: 10.1016/j.phrs.2016.01.005. View